---
figid: PMC9230742__pharmaceutics-14-01156-g006
figtitle: Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib,
  CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment
  in NSCLC Tumor Xenografts
organisms:
- NA
pmcid: PMC9230742
filename: pharmaceutics-14-01156-g006.jpg
figlink: /pmc/articles/PMC9230742/figure/pharmaceutics-14-01156-f006/
number: F6
caption: 'Plausible mechanism of action of CFM4.17, Telmisartan and Osimertinib combination
  against non-small cell lung cancers in athymic nude mice. Telmisartan activates
  the PPAR-γ nuclear receptor, CFM4.17 acts on CARP-1, and Osimertinib inhibits the
  EGFR mutated gene, increasing AMPK activity and thus regulating the p38 MAPkinase
  pathway, Lamin B2 protein, JAK-STAT pathway, PDL-1, and NF-κB pathway to maintain
  apoptosis, cancer metastasis, and immune suppression. Bcl-2: B-cell lymphoma 2,
  Bax: BCL2-associated X protein, CARP-1: Cell cycle and apoptosis regulatory protein
  1, EGFR: epidermal growth factor receptor, CFM-F: lipid formulation of CFM4.17,
  MMP-1: Matrix metalloproteinase-1, OSM: Osimertinib, PD-L1: Programmed cell death
  1 ligand 1, STAT3: Signal transducer and activator of transcription 3, SOX2: SRY-Box
  Transcription Factor 2, TLM: Telmisartan.'
papertitle: Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib,
  CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment
  in NSCLC Tumor Xenografts.
reftext: Ramesh Nimma, et al. Pharmaceutics. 2022 Jun;14(6):1156.
year: '2022'
doi: 10.3390/pharmaceutics14061156
journal_title: Pharmaceutics
journal_nlm_ta: Pharmaceutics
publisher_name: MDPI
keywords: epidermal growth factor receptor | non-small cell lung cancer | Lamin B2
  | AMPK | Osimertinib | RNA seq | proteomics | RT-PCR
automl_pathway: 0.9322752
figid_alias: PMC9230742__F6
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC9230742__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9230742__pharmaceutics-14-01156-g006.html
  '@type': Dataset
  description: 'Plausible mechanism of action of CFM4.17, Telmisartan and Osimertinib
    combination against non-small cell lung cancers in athymic nude mice. Telmisartan
    activates the PPAR-γ nuclear receptor, CFM4.17 acts on CARP-1, and Osimertinib
    inhibits the EGFR mutated gene, increasing AMPK activity and thus regulating the
    p38 MAPkinase pathway, Lamin B2 protein, JAK-STAT pathway, PDL-1, and NF-κB pathway
    to maintain apoptosis, cancer metastasis, and immune suppression. Bcl-2: B-cell
    lymphoma 2, Bax: BCL2-associated X protein, CARP-1: Cell cycle and apoptosis regulatory
    protein 1, EGFR: epidermal growth factor receptor, CFM-F: lipid formulation of
    CFM4.17, MMP-1: Matrix metalloproteinase-1, OSM: Osimertinib, PD-L1: Programmed
    cell death 1 ligand 1, STAT3: Signal transducer and activator of transcription
    3, SOX2: SRY-Box Transcription Factor 2, TLM: Telmisartan.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - TP53
  - TP63
  - TP73
  - AGA
  - BAX
  - SF3B2
  - RNF34
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - NEUROD1
  - TUBB4B
  - TGFB1
  - TGFB2
  - TGFB3
  - NFKB1
  - BCL2
  - OSM
  - CCM2
  - STAT3
  - SOX2
  - MMP1
  - EGFR
  - CD274
---
